drugset

drugset / Trial / NCT05453695

Intravenous DNase I for the Treatment of Sepsis (IDEALSepsisI)

NCT05453695 ↗

Phase 1 Recruiting 36 enrolled McMaster University Canadian Institutes of Health Research (CIHR) · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

Phase I dose-escalation safety and feasibility of IV DNase I in ICU septic patients.

Timeline

Start: 2023-01-17
Primary completion: 2026-05-28
Completion: 2026-09-30

Publications

Sharma N, Dwivedi DJ, Fux L, Hayon Y, Ruderfer I, Nataf Y, Cani E, Liaw PC. Intravenous Delivery of Long-Acting Dnase I (PRX-119) In a Murine Model of Polymicrobial Abdominal Sepsis. Shock. 2026 Jan 1;65(1):76-84. doi: 10.1097/SHK.0000000000002666. Epub 2025 Jul 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DNase I	Protein / enzyme biologic	25 ug/kg	Intravenous
Subject	DNase I	Protein / enzyme biologic	125 ug/kg	Intravenous

Indications